Recent News

• 11.05.2026 - Certara Reports Third Quarter 2026 Financial Results
• 10.30.2026 - From PK Data to Document: An AI-Driven Daytrip with Phoenix Cloud
• 10.28.2026 - What is new in Phoenix 8.9?
• 10.26.2026 - Bridging Oncology and Autoimmune Disease: Using QSP to Select T-Cell Engager Doses by CRS Risk and Efficacy
• 10.20.2026 - Leveraging a QSP Platform for Prediction of Clinical Efficacy and Safety Biomarkers in Immuno-Oncology Combination Therapy
• 10.19.2026 - From Sketch to Insight: Drawing and Property Calculation with Marvin and Chemically Intelligent Toolkits
• 10.19.2026 - Certara Biotech Forum London: Building an Investor-Ready Strategy and Story
• 10.13.2026 - 2nd Model-Informed Drug Development Summit
• 10.13.2026 - From Data to Decisions: Getting More from Clinical Trial Evidence
• 10.08.2026 - Drug-Drug Interaction (DDI) Calculator

Recent Filings

• 11.05.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.05.2026 - 8-K Current report
• 11.05.2026 - EX-99.1 EX-99.1
• 09.03.2026 - 144 Report of proposed sale of securities
• 09.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.07.2026 - 8-K Current report
• 08.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.04.2026 - 8-K Current report
• 08.04.2026 - 8-K Current report
• 07.17.2026 - 3 Initial statement of beneficial ownership of securities